Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
18.71
+0.43 (2.35%)
At close: Sep 18, 2026, 4:00 PM EDT
19.18
+0.47 (2.51%)
After-hours: Sep 18, 2026, 7:49 PM EDT
Amneal Pharmaceuticals Revenue
Amneal Pharmaceuticals had revenue of $796.20M in the quarter ending June 30, 2026, with 9.89% growth. This brings the company's revenue in the last twelve months to $3.12B, up 9.28% year-over-year. In the year 2025, Amneal Pharmaceuticals had annual revenue of $3.02B with 8.05% growth.
Revenue (ttm)
$3.12B
Revenue Growth
+9.28%
P/S Ratio
2.09
Revenue / Employee
$358,339
Employees
8,700
Market Cap
6.52B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.02B | 224.80M | 8.05% |
| Dec 31, 2024 | 2.79B | 400.35M | 16.73% |
| Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
| Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
| Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
| Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
| Dec 31, 2019 | 1.63B | -36.62M | -2.20% |
| Dec 31, 2018 | 1.66B | 629.34M | 60.88% |
| Dec 31, 2017 | 1.03B | 15.43M | 1.52% |
| Dec 31, 2016 | 1.02B | 151.95M | 17.54% |
| Dec 31, 2015 | 866.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Elanco Animal Health | 5.02B |
| Dr. Reddy's Laboratories | 3.50B |
| Neurocrine Biosciences | 3.37B |
| Hims & Hers Health | 2.58B |
| Alkermes | 1.67B |
| Lantheus Holdings | 1.56B |
| Indivior Pharmaceuticals | 1.33B |
| Kiniksa Pharmaceuticals International, | 840.85M |
AMRX News
- 1 day ago - Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide - TheFly
- 1 day ago - Amneal Announces FDA Approval and Launch of Lanreotide Injection - GlobeNewsWire
- 2 days ago - Amneal Pharmaceuticals price target raised to $20 from $16 at Barclays - TheFly
- 10 days ago - Leerink bullish on Amneal Pharmaceuticals, initiates with an Outperform - TheFly
- 10 days ago - Amneal Pharmaceuticals initiated with an Outperform at Leerink - TheFly
- 24 days ago - Amneal Pharmaceuticals resumed with an Overweight at JPMorgan - TheFly
- 5 weeks ago - Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader - GlobeNewsWire
- 6 weeks ago - Amneal Pharmaceuticals price target raised to $25 from $23 at UBS - TheFly